LDS/Medical Tests/TPMT (Thiopurine S-methyltransferase) Genotyping

TPMT (Thiopurine S-methyltransferase) Genotyping

The thiopurine drugs, 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), and azathioprine (AZA), are purine antimetabolites that are used in the therapeutic management of leukemias, particularly acute lymphoblastic leukemia (ALL) in children. They are also used in the treatment of various clinical conditions, including rheumatic disease, inflammatory bowel disease, and solid organ transplantation. These agents are prodrugs that require intracellular activation to 6-thioguanine nucleotides (6-TGN). The cytotoxicity of the thiopurine drugs is achieved by incorporation of 6-TGN into DNA and RNA. The synthetic pathway of cytotoxic 6-TGN is in competition with the inactivation pathway catalyzed by thiopurine methyltransferase (TPMT). Outside the bone marrow, these agents can be oxidatively inactivated by xanthine oxidase or methylated by TPMT. However, in the hematopoietic tissue, TPMT is only the significant inactivation pathway because the effect of xanthine oxidase is negligible. Thus, hematopoietic tissues are susceptible to damage in cases in which TPMT activity is very low. Patients with low TPMT activity are at significantly greater risk of toxicity and often need a lower dose of these drugs. Therefore, TPMT is used as a pharmacogenetic marker for the individualizing drug therapy based on a patient’s biochemical phenotype or genotype and the prospective determination of functional TPMT status is useful for preventing 6-MP toxicity.

The TPMT activity is highly variable in all large population. The TPMT gene is located on chromosome 6p22.3 and is 26,833 bases long, exhibiting genetic polymorphism in all population. Approximately 90% of individuals have two copies of “wild type” TPMT gene resulting in high activity, 10% have one copy of the wild-type gene and one copy of a gene variation (heterozygous) associated with intermediate activity. Approximately 0.3% have both copies of TPMT with variations (homozygous) resulting in low or undetectable enzyme activity. At least 28 TPMT alleles have been identified, including single-nucleotide polymorphisms (SNPs) that lead to amino acid substitution, formation of a stop codon, or a change that destroys a splice site. Four alleles, TPMT2 (238G>C), TPMT3A (460G>A and 719A>G), TPMT3B (460G>A), and TPMT3C (719A>G), account for 80 to 90% of intermediate or low enzyme activity. TPMT genotype correlates well with TPMT activity in leukemia cells and thus aids to determine prospective toxicity associated with 6-MP and AZA.

  • To evaluate potential efficacy and/or toxicity of thiopurine drugs, 6-mercaptopurine, 6-thioguanine, and azathiopurine

Drugs metabolized by TPMT are Antiproliferative agents: Mycophenolate Mofetil, Mycophenolate sodium, and Azathioprine.

TPMT Nucleotide Change Effect on Enzyme Metabolism (phenotype)

*1 None (wild type) Extensive (normal) metabolizer

*2 c.238G->C Nonfunctional, no activity

*3A c.460G->A and c.719A->G Nonfunctional, no activity

*3B c.460G->A Nonfunctional, no activity

*3C c.719A-> Nonfunctional, no activity

*4 c.626-1G-> Nonfunctional, no activity

*5 c.146T->C Nonfunctional, no activity

*8 c.644G->A Reduced-function/decreased activity

*12 c.374C->T Reduced-function/decreased activity

  • Heterozygous for one normal and one nonfunctional variant (TPMT1/2) or any nonfunctional allele (3A, 3B, 3C, 4, 5, 8, *12) will result in intermediate metabolizer phenotype.
  • If homozygous, or where two nonfictional variants TPMT2/2) or any nonfunctional allele (2, 3A, 3B, 3C, or *4) will result in poor metabolizer phenotype.

Alternative agents should be considered. If using azathioprine, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. Azathioprine is the likely cause of myelosuppression

TPMT*1/*1

Polymerase Chain Reaction (PCR) and Allele Specimen Primer Extension (ASPE), Sequencing.

Whole blood (EDTA), Buccal swab.

Stability (blood):

  • Ambient: 5-7 days
  • Refrigerated: 7-14 days
Erythrocytes TPMT activity, blood 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) levels.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login